fycompa
fycompa Uses, Dosage, Side Effects, Food Interaction and all others data.
fycompa is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
fycompa is involved in inhibiting neuronal excitation in the central nervous system leading to such effects as decreased pyschomotor performance.
Trade Name | fycompa |
Availability | Prescription only |
Generic | Perampanel |
Perampanel Other Names | Perampanel, Pérampanel, Perampanelum |
Related Drugs | gabapentin, clonazepam, lamotrigine, diazepam, pregabalin, Lyrica, topiramate, levetiracetam, Keppra, Topamax |
Weight | 10mg, 12mg, 2mg, 4mg, 6mg, 8mg, , 0.5mg/ml |
Type | Tablet, Film Coated, Oral Suspension, Oral Tablet |
Formula | C23H15N3O |
Weight | Average: 349.393 Monoisotopic: 349.121512115 |
Protein binding | Perampanel is 95-96% plasma protein bound with most binding to the plasma proteins α1-acid glycoprotein and albumin. |
Groups | Approved |
Therapeutic Class | |
Manufacturer | Eisai Europe Limited, Eisai Ltd, Eisai Pharmaceuticals |
Available Country | Saudi Arabia, Canada, United Kingdom, India, United States, Netherlands, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
fycompa is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy.
Used in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
fycompa is also used to associated treatment for these conditions: Grand mal Generalized tonic-clonic seizure, Partial-Onset Seizures
How fycompa works
The exact mechanism of action of perampanel in seizures is not yet determined, but it is known that perampanel decreases neuronal excitation by non-competitive ihibition of the AMPA receptor.
Toxicity
The FDA label includes an important warning of serious or life-threatening behavioral and psychiatric adverse reactions including aggression, hostility, irritability, anger, and homicidal thoughts in patients taking perampanel.
Food Interaction
- Take with or without food. Food slows the rate of absorption but not the extent.
[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.
Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.
Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
fycompa Cholesterol interaction
[Moderate] Increased levels of triglycerides have occurred in patients using perampanel.
Care should be taken when prescribing this agent to patients with high triglycerides levels, and close monitoring of lipid profile is recommended during therapy.
fycompa Drug Interaction
Moderate: aripiprazole, lorazepam, diphenhydramine, brivaracetam, divalproex sodium, levetiracetam, lamotrigine, escitalopram, pregabalin, clobazam, quetiapine, topiramate, sertraline, cetirizineUnknown: fluticasone nasal, esomeprazole, montelukast, lacosamide, cyanocobalamin, cholecalciferol
fycompa Disease Interaction
Major: renal impairmentModerate: suicidal tendency, elevated triglycerides, weight gain, Perampanel – hepatic impairment
Volume of Distribution
The volume of distribution of perampanel was not quantified.
Elimination Route
After oral adminitration, perampanel is absorbed rapidly and completely.
Half Life
fycompa has a long elmination half-life of about 105 hours.
Clearance
In healthy patients, perampanel has a clearance of about 12 mL/min.
Elimination Route
fycompa is eliminated mostely in the feces (48%) and to a lesser exten in the urine (22%).
Innovators Monograph
You find simplified version here fycompa